Akero Therapeutics, Inc. Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRO

Rank in Stocks #3736
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
Share Price
$54.65
Last synced: 2025-12-09
Market Cap
$4.50B
Change (1 day)
0.00%
Change (1 year)
1.50%
Country
US
Trade Akero Therapeutics, Inc. (AKRO)

Category

Healthcare
Dividend history for Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (stock symbol: AKRO) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Akero Therapeutics, Inc. (AKRO) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL